Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference
Autolus is advancing its lead program, AUTO1 in relapsed/refractory adult acute lymphoblastic leukemia (ALL) patients, into a potential pivotal trial in the
Autolus will continue in 2020 to progress additional next generation programs through pre-clinical development and expand its suite of cell programming technologies to include programming modules designed for allogeneic applications. A first novel allogeneic application is expected to enter the clinic in the fourth quarter of 2020.
“2020 promises to be an exciting year for Autolus. We believe our lead program, AUTO1, has the potential to be the best-in-class CD19 CAR T in ALL and we are focused on advancing this program into a potential pivotal study,” said Dr.
About
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the anticipated development of Autolus’ product candidates, including its intentions regarding the timing for providing further updates on the development of its product candidates. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed on
Contacts:
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com
+44 (0) 7818 430877
j.wilson@autolus.com
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
Source: Autolus Therapeutics plc